Publication Information

{'id': 'https://openalex.org/W3084048569', 'doi': 'https://doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2', 'title': 'Advances of treatment with IL-6/IL-6 receptor inhibitors for RA', 'display_name': 'Advances of treatment with IL-6/IL-6 receptor inhibitors for RA', 'publication_year': 2018, 'publication_date': '2018-01-01', 'ids': {'openalex': 'https://openalex.org/W3084048569', 'doi': 'https://doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2', 'mag': '3084048569'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2', 'pdf_url': 'https://www.jstage.jst.go.jp/article/jpssuppl/WCP2018/0/WCP2018_SY61-2/_pdf', 'source': {'id': 'https://openalex.org/S4210239061', 'display_name': 'Proceedings for Annual Meeting of The Japanese Pharmacological Society', 'issn_l': '2435-4953', 'issn': ['2435-4953'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4310313602', 'host_organization_name': 'Japanese Pharmacological Society', 'host_organization_lineage': ['https://openalex.org/P4310313602'], 'host_organization_lineage_names': ['Japanese Pharmacological Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://www.jstage.jst.go.jp/article/jpssuppl/WCP2018/0/WCP2018_SY61-2/_pdf', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5081181665', 'display_name': 'Toshihiro Nanki', 'orcid': 'https://orcid.org/0000-0002-3482-074X'}, 'institutions': [{'id': 'https://openalex.org/I129634264', 'display_name': 'Toho University', 'ror': 'https://ror.org/02hcx7n63', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I129634264']}], 'countries': ['JP'], 'is_corresponding': True, 'raw_author_name': 'Toshihiro Nanki', 'raw_affiliation_strings': ['Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Japan'], 'affiliations': [{'raw_affiliation_string': 'Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Japan', 'institution_ids': ['https://openalex.org/I129634264']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': ['https://openalex.org/A5081181665'], 'corresponding_institution_ids': ['https://openalex.org/I129634264'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 62}, 'biblio': {'volume': 'WCP2018', 'issue': '0', 'first_page': 'SY61', 'last_page': '2'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11503', 'display_name': 'Cytokine Signaling Pathways and Interactions', 'score': 0.9252, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11503', 'display_name': 'Cytokine Signaling Pathways and Interactions', 'score': 0.9252, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/tocilizumab', 'display_name': 'Tocilizumab', 'score': 0.9895444}], 'concepts': [{'id': 'https://openalex.org/C2777178219', 'wikidata': 'https://www.wikidata.org/wiki/Q425154', 'display_name': 'Tocilizumab', 'level': 3, 'score': 0.9895444}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.80286276}, {'id': 'https://openalex.org/C203014093', 'wikidata': 'https://www.wikidata.org/wiki/Q101929', 'display_name': 'Immunology', 'level': 1, 'score': 0.50176907}, {'id': 'https://openalex.org/C2777575956', 'wikidata': 'https://www.wikidata.org/wiki/Q187255', 'display_name': 'Rheumatoid arthritis', 'level': 2, 'score': 0.48049107}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2', 'pdf_url': 'https://www.jstage.jst.go.jp/article/jpssuppl/WCP2018/0/WCP2018_SY61-2/_pdf', 'source': {'id': 'https://openalex.org/S4210239061', 'display_name': 'Proceedings for Annual Meeting of The Japanese Pharmacological Society', 'issn_l': '2435-4953', 'issn': ['2435-4953'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4310313602', 'host_organization_name': 'Japanese Pharmacological Society', 'host_organization_lineage': ['https://openalex.org/P4310313602'], 'host_organization_lineage_names': ['Japanese Pharmacological Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2', 'pdf_url': 'https://www.jstage.jst.go.jp/article/jpssuppl/WCP2018/0/WCP2018_SY61-2/_pdf', 'source': {'id': 'https://openalex.org/S4210239061', 'display_name': 'Proceedings for Annual Meeting of The Japanese Pharmacological Society', 'issn_l': '2435-4953', 'issn': ['2435-4953'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4310313602', 'host_organization_name': 'Japanese Pharmacological Society', 'host_organization_lineage': ['https://openalex.org/P4310313602'], 'host_organization_lineage_names': ['Japanese Pharmacological Society'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3', 'score': 0.54}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3108674512', 'https://openalex.org/W3032375762', 'https://openalex.org/W3031052312', 'https://openalex.org/W2899084033', 'https://openalex.org/W2748952813', 'https://openalex.org/W2604872355', 'https://openalex.org/W2080531066', 'https://openalex.org/W2048182022', 'https://openalex.org/W1995515455', 'https://openalex.org/W1506200166'], 'abstract_inverted_index': {'Interleukin': [0], '(IL)-6': [1], 'has': [2, 106, 150], 'a': [3, 63, 87], 'wide': [4], 'range': [5], 'of': [6, 16, 23, 35, 45, 83, 170, 174, 206, 243, 246, 248, 255], 'effects': [7, 212], 'on': [8, 99], 'immune': [9], 'cells': [10], 'and': [11, 41, 47, 49, 53, 74, 116, 144, 156, 177, 182, 213, 233, 251], 'contributes': [12], 'to': [13, 61, 80], 'the': [14, 20, 81, 84, 114], 'pathogenesis': [15], 'autoimmune': [17], 'diseases.': [18], 'In': [19], 'synovial': [21], 'tissue': [22], 'rheumatoid': [24], 'arthritis': [25, 115, 143], '(RA),': [26], 'fibroblast-like': [27], 'synoviocytes': [28], 'mainly': [29], 'expressed': [30], 'IL-6,': [31], 'which': [32, 78], 'induces': [33, 179], 'production': [34], 'inflammatory': [36], 'mediators,': [37], 'such': [38], 'as': [39, 86, 199, 201, 219], 'chemokines': [40], 'adhesion': [42], 'molecules,': [43], 'enhancement': [44], 'angiogenesis': [46], 'osteoclastogenesis,': [48], 'differentiation': [50], 'into': [51], 'Th17': [52], 'plasma': [54], 'cell.': [55], 'Therefore,': [56], 'IL-6': [57, 68, 72, 75, 207, 256, 267], 'signaling': [58, 257], 'was': [59, 97, 137, 190], 'thought': [60], 'be': [62, 163, 271], 'therapeutic': [64], 'target': [65], 'for': [66, 103, 113, 134, 140, 153, 165, 193, 217, 228, 240, 260], 'RA.': [67, 104, 135, 229, 261], 'is': [69, 111, 125, 129, 258, 263], 'engaged': [70], 'by': [71], 'receptor': [73, 93], 'signal': [76], 'transducer/gp130,': [77], 'leads': [79], 'formation': [82], 'dimer': [85], 'signaling-competent': [88], 'hexamer.': [89], 'Tocilizumab,': [90], 'humanized': [91], 'anti-IL-6': [92, 188, 223], 'monoclonal': [94], 'antibody': [95], '(mAb),': [96], 'launched': [98], '2008': [100], 'in': [101, 195], 'Japan': [102], 'It': [105, 262], 'been': [107, 151], 'shown': [108], 'that': [109, 265], 'tocilizumab': [110, 149, 171, 202], 'effective': [112, 164, 259], 'also': [117, 126, 138, 162, 225], 'inhibits': [118], 'bone': [119], 'destruction.': [120], 'Tocilizumab': [121, 128, 136, 160], 'monotherapy,': [122], 'without': [123], 'methotrexate,': [124], 'effective.': [127], 'now': [130], 'world': [131], 'widely': [132], 'used': [133, 139], 'juvenile': [141], 'idiopathic': [142], 'Castleman': [145], 'disease.': [146], 'Moreover,': [147], 'recently': [148], 'approved': [152, 192], 'Takayasu': [154], 'arteritis': [155], 'giant': [157], 'cell': [158], 'arteritis.': [159], 'may': [161], 'polymyalgia': [166], 'rheumatica.': [167], 'However,': [168, 230], 'treatment': [169], 'increases': [172], 'frequency': [173], 'serious': [175], 'infection': [176], 'sometimes': [178], 'neutrocytopenia,': [180], 'thrombocytopenia,': [181], 'dyslipidemia.': [183], 'Sarilumab,': [184], 'human': [185, 222], 'mAb': [186], 'against': [187], 'receptor,': [189], 'just': [191], 'RA': [194, 218, 241], 'this': [196], 'year.': [197], 'Sarilumab': [198, 209], 'well': [200], 'binds': [203], 'domain': [204], '2': [205], 'receptor.': [208], 'showed': [210, 226], 'similar': [211, 214], 'adverse': [215], 'events': [216], 'tocilizumab.': [220], 'Sirukumab,': [221], 'mAb,': [224], 'efficacy': [227], 'US': [231], 'Food': [232], 'Drug': [234], 'Administration': [235], 'did': [236], 'not': [237], 'approve': [238], 'it': [239], 'because': [242], 'slight': [244], 'increase': [245], 'numbers': [247], 'dead': [249], 'patients': [250], 'cardiovascular': [252], 'events.': [253], 'Blockade': [254], 'expected': [264], 'more': [266], 'blocking': [268], 'drugs': [269], 'will': [270], 'developed.': [272]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3084048569', 'counts_by_year': [], 'updated_date': '2024-12-13T06:33:09.009261', 'created_date': '2020-09-14'}